Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.8%

11 terminated/withdrawn out of 228 trials

Success Rate

95.2%

+8.7% vs industry average

Late-Stage Pipeline

24%

54 trials in Phase 3/4

Results Transparency

66%

143 of 217 completed trials have results

Key Signals

143 with results9 terminated

Enrollment Performance

Analytics

Phase 2

70(46.1%)

Phase 3

45(29.6%)

Phase 1

28(18.4%)

Phase 4

9(5.9%)

152Total

Phase 2(70)

Phase 3(45)

Phase 1(28)

Phase 4(9)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (228)

Showing 20 of 228 trials

NCT01255891Phase 2Completed

Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate

Role: collaborator

NCT01123876Phase 1Completed

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Role: lead

NCT01063816Phase 1Completed

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Role: lead

NCT00406809Phase 1Completed

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Role: lead

NCT01715415Phase 3Completed

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Role: lead

NCT01690195Phase 2Terminated

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Role: lead

NCT01676935Phase 2Terminated

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Role: lead

NCT01506947Phase 4Completed

A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients

Role: lead

NCT01685203Phase 2Completed

A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection

Role: lead

NCT01736176Phase 3Completed

A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease

Role: lead

NCT01441635Phase 2Completed

Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

Role: lead

NCT01468233Phase 3Completed

Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa

Role: lead

NCT01674725Phase 3Completed

A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C

Role: lead

NCT01166282Phase 3Completed

A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis

Role: lead

NCT01716585Phase 3Completed

A Study to Evaluate Chronic Hepatitis C Infection

Role: lead

NCT01767116Phase 3Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection

Role: lead

NCT01704755Phase 3Completed

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis

Role: lead

NCT01064856Phase 3Completed

Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)

Role: lead

NCT01468207Phase 3Completed

Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa

Role: lead

NCT00573794Phase 3Completed

Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis

Role: lead